50 results on '"Ruiz, Josel D."'
Search Results
2. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
3. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation
4. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma
5. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
6. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
7. Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation
8. Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology
9. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
10. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves
11. Abstract A48: Aging-related, Senescence-associated Secretory Phenotype and Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults
12. Prospective Geriatric Assessment and Geriatric Consultation in CAR T-cell Therapy for Older Lymphoma Patients
13. Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
14. Utility of Routine Pulmonary Function Test after Autologous Hematopoietic Cell Transplantation in Lymphoma
15. The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
16. Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation
17. Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy
18. Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults
19. Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas
20. Comparison of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin Lymphoma
21. Hematopoietic Recovery Following Chimeric Antigen Receptor T Cell (CAR T) Therapy in Hematological Malignancies
22. Renal Effects and Recovery in Patients Receiving Chimeric Antigen Receptor T Cell Therapy
23. Acute Kidney Injury in Allogeneic Hematopoietic Transplant Recipients
24. Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell
25. Time to Relapse and the Patterns of Relapse Are Prognostic for Post-Relapse Survival after CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma
26. Long-Term Survival in Patients with AML or MDS Relapsed after Allogeneic Hematopoietic Cell Transplantation: Importance of Second Cell Therapy
27. Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/Dl Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response (RR) at 1 Year in Light Chain (AL) Amyloidosis
28. Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores.
29. 502 - Utility of Routine Pulmonary Function Test after Autologous Hematopoietic Cell Transplantation in Lymphoma
30. 191 - Peri-Transplant Vitamin and Micronutrient Status in Allogeneic Hematopoietic Cell Transplantation
31. Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
32. Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
33. The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment
34. Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis
35. 430 - High Rates of Residual Vaccine Titers at 1-Year Post CD19 Chimeric Antigen Receptor T Cell Therapy
36. 349 - Reflectance Confocal Microscopy Detects Pathologic Changes in Normal-Appearing Skin of Patients with Cutaneous Graft-Versus-Host Disease after Day 100 Post Allogeneic Stem Cell Transplantation
37. 350 - Real-Time Reflectance Confocal Microscopy Features of Cutaneous Graft-Versus-Host Disease
38. 87 - Reflectance Confocal Microscopy Correlates with Histopathology in Nonsclerotic GvHD and Non-GvHD Rash after Day 100 Post Allogeneic Stem Cell Transplantation
39. 71 - Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
40. 25 - A Simplified Comorbidity Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
41. Real-Time Reflectance Confocal Microscopy Features of Cutaneous Graft-Versus-Host Disease
42. Reflectance Confocal Microscopy Detects Pathologic Changes in Normal-Appearing Skin of Patients with Cutaneous Graft-Versus-Host Disease after Day 100 Post Allogeneic Stem Cell Transplantation
43. Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
44. Reflectance Confocal Microscopy Correlates with Histopathology in Nonsclerotic GvHD and Non-GvHD Rash after Day 100 Post Allogeneic Stem Cell Transplantation
45. A Simplified Comorbidity Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
46. Peri-Transplant Vitamin and Micronutrient Status in Allogeneic Hematopoietic Cell Transplantation
47. High Rates of Residual Vaccine Titers at 1-Year Post CD19 Chimeric Antigen Receptor T Cell Therapy
48. Antithymocyte globulin exposure in CD34+T-cell depleted allogeneic hematopoietic cell transplantation
49. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
50. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.